Standard monotherapies often fail to maintain long-term efficacy due to drug-drug interactions or immune evasion. Combining specific inhibitors with antibodies addresses the limitation of transient clinical benefit.

Uncontrolled liberation of cytotoxic agents before reaching target tissues causes off-target toxicity. Targeted enzymatic cleavage ensures localized activation and improves the therapeutic index.

Low retention and weak binding of radiopharmaceuticals to target cells limit therapeutic efficacy. Increasing valency through multimeric structures overcomes rapid clearance and suboptimal target accumulation.